


0300



Docket No. 51400-B/JPW/AJM/MML

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Donald W. Landry
Serial No. : 09/940,727
Filed : August 28, 2001
For : ANTI-COCAINE CATALYTIC ANTIBODY

1185 Avenue of the Americas
New York, New York 10036
April 3, 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with his duty of disclosure under 37 C.F.R. §1.56, applicant directs the Examiner's attention to the following references which are listed on the PTO-1449 form attached hereto as **Exhibit A**.

1. U.S. Patent No. 3,888,866, issued June 10, 1975, Leute, et al.;
2. U.S. Patent No. 3,917,582, issued November 4, 1975, Soffer, et al.;
3. U.S. Patent No. 3,975,237, issued August 17, 1976, Rubenstein et al.;
4. U.S. Patent No. 4,045,420, issued August 30, 1977, Soffer, et al.;
5. U.S. Patent No. 4,197,237, issued April 8, 1980, Leute, et al.;
6. U.S. Patent No. 4,203,802, issued May 20, 1980, Rubenstein, et al.;

Applicant: Donald W. Landry
U.S. Serial No.: 09/940,727
Filed: August 28, 2001
Page 2

7. U.S. Patent No. 4,235,864, issued November 25, 1980, Kaul, et al.;
8. U.S. Patent No. 4,659,567, issued April 21, 1987, Tramontano, et al.;
9. U.S. Patent No. 4,792,446, issued December 20, 1988, Kim, et al.;
10. U.S. Patent No. 4,963,355, issued October 16, 1990, Kim, et al.;
11. U.S. Patent No. 5,030,717, issued July 9, 1991, Tramontano, et al.;
12. U.S. Patent No. 5,079,152, issued January 7, 1992, Benkovic, et al.;
13. U.S. Patent No. 5,202,270, issued April 13, 1993, Ungemach, et al.;
14. U.S. Patent No. 5,463,028, issued October 31, 1995, Landry, et al.;
15. U.S. Patent No. 5,948,658, issued September 7, 1999, Landry;
16. U.S. Patent No. 5,977,314, issued November 2, 1999, Landry et al.;
17. U.S. Patent No. 5,990,285, issued November 23, 1999, Landry et al.;
18. PCT International Application No. WO 93/20076, published October 14, 1993;

Applicant: Donald W. Landry
U.S. Serial No.: 09/940,727
Filed: August 28, 2001
Page 3

19. Abraham, et al., "N-Modified Analogues of Cocaine: Synthesis and Inhibition of Binding to the Cocaine Receptor," *J. Med. Chem.*, 35:141-144 (1992);
20. Ambre, J., et al., "Urinary excretion of ecgonine methyl ester, a major metabolite of cocaine in humans," *J. Anal. Toxicol.*, 8:23-25 (1984);
21. Ambre, J., "The urinary excretion of cocaine and metabolites in humans: a kinetic analysis of published data," *J. Anal. Toxicol.*, 9:241-245 (1985);
22. Basmadjian et al., "Generation of Polyclonal Catalytic Antibodies Against Cocaine Using Transition State Analogs of Cocaine Conjugated to Diphtheria Toxoid," *Chem. & Pharm. Bull.*, Vol. 43, No. 11:1902-1911 (1995);
23. Chandrakumar, et al., "Phenylphosphonate monoester analogs of cocaine," *Bioorg. & Medic. Chem. Lett.*, 3:309-312 (1993);
24. Landry, et al., "Antibody-Catalyzed Degradation of Cocaine," *Science*, 259:1899-1901 (1993);
25. Landry, "Anti-cocaine catalytic antibodies: A Novel Approach to Addiction," *Abstracts of Papers Amer. Chem. Soc.*, 209, No. 1-2, ANYL 19, Abstract No. XP000992924 (1995);
26. Landry et al., "Anti-cocaine catalytic antibodies: A Novel Approach To The Problem Of Addiction," *Journal of Addictive Diseases*, Vol. 16, No. 3:1-17 (1997);

Applicant: Donald W. Landry
U.S. Serial No.: 09/940,727
Filed: August 28, 2001
Page 4

27. Lewin, et al., "2 beta-substituted Analogues of Cocaine. Synthesis and Inhibition of Binding to the Cocaine Receptor." *J. Med. Chem.* 35:135-140 (1992);
28. Schultz, P.G., "The interplay between chemistry and biology in the design of enzymatic catalysts," *Science*, 240:426-433 (1988);
29. Tramontano, et al., "Catalytic antibodies," *Science*, 234:1566-1570 (1986);
30. Tramontano, et al., "Antibody catalysis approaching the activity of enzymes," *J. Am. Chem. Soc.*, 110:2282-2286 (1988);
31. Tramontano, et al., "Chemical reactivity at an antibody binding site elicited by mechanistic design of a synthetic antigen," *Proc. Natl. Acad. Sci. USA*, 83:6736-6740 (1986);
and
32. Yang, et al., "Anti-Cocaine Catalytic Antibodies: A Synthetic Approach To Improved Antibody Diversity," *J. Am. Chem. Soc.*, 118: No. 25, 5881-5890 (1996).


Applicant: Donald W. Landry
U.S. Serial No.: 09/940,727
Filed: August 28, 2001
Page 5

Items 1-32 were previously submitted to the United States Patent and Trademark Office in connection with prior application U.S. Serial No. 08/672,345, filed June 25, 1996, now U.S. Patent No. 5,948,658, issued September 7, 1999, of which this application is a continuation-in-part. Pursuant to M.P.E.P. §609(I)(A)(2), applicant need not resubmit copies of the cited references in order for them to be considered in this application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorneys invite the Examiner to telephone them at the number provided below.


No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Alan J. Morrison
Registration No. 37,399
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Assistant Commissioner for Patents,
Washington, D.C. 20231.


Alan J. Morrison
Reg. No. 37,399

7/3/02
Date